Skip to content

Intervention study of the patients with mild depressive mood after percutaneous coronary intervention in the treatment of the patients with collateral vessels based on the hypothesis of

Intervention study of the patients with mild depressive mood after percutaneous coronary intervention in the treatment of the patients with collateral vessels based on the hypothesis of

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-15007378
Enrollment
Unknown
Registered
2015-11-11
Start date
1990-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

the patients with mild depressive mood after percutaneous coronary intervention

Interventions

1:Drug group
2:Simulated drugs group
3:antidepressant

Sponsors

The first clinical medical college of Beijing University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. accord with the diagnostic criteria of TCM syndrome differentiation of depression; 2. accord with the diagnostic criteria of depressive episode of Western medicine; 3. HAMD Depression Scale (24 items), scoring more than 8 cent, less than 35 points; 4. has been performed coronary heart disease PCI surgery; 5. the vital signs are stable, the consciousness is clear, has certain expression ability; 6. aged 18-80 years old, willing to try and cooperate with patients, men and women are not limited; 7. the informed consent, volunteer subjects. The process of obtaining informed consent shall be in accordance with the provisions of the GCP (drug clinical trial management specification).

Exclusion criteria

Exclusion criteria: 1. There are serious suicide; 2. Because of the low degree of culture, language differences, disturbance of consciousness, dementia, aphasia, deafness, agnosia influence emotional expression and not according to the prescribed medication; 3. patients with severe or unstable heart, liver, kidney, endocrine, thyroid dysfunction, blood and other diseases in the Department of internal medicine; 4. had a history of epilepsy, cerebral trauma; 5. alcohol and drug dependence in a year; 6. secondary to other mental illness or physical disease of the depressive episode; 7. with other serious psychiatric symptoms, such as hallucinations, paranoia and other symptoms; 8. pregnant women who are pregnant, pregnant, or likely to be pregnant during the trial; 9. of the superconducting transdermal medicine for treating drug components and paroxetine hydrochloride have allergic history; 10. in 30 days to participate in clinical trials of other drugs; 11. can not take the medicine according to the doctor's advice.

Design outcomes

Primary

MeasureTime frame
5-HT content;HAMD Depression Rating Scale;

Secondary

MeasureTime frame
Seattle angina questionnaire scale;

Countries

China

Contacts

Public ContactWang zhen
1282174720@qq.com+86 13001240944

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026